Novel Multi-component Nanopharmaceuticals for Anti-HIV Effects
Current anti-acquired immunodeficiency syndrome (AIDS) therapeutic agents and treatment regimens can provide a dramatically improved quality of life for human immunodeficiency virus (HIV)–positive people, many of whom have no detectable viral load for prolonged periods of time. Despite this, curing AIDS remains an elusive goal, partially due to the occurrence of drug resistance. Since the development of resistance is linked to, among other things, fluctuating drug levels, our long-term goal has been to develop nanotechnology-based drug delivery systems that can improve therapy by more precisely controlling drug concentrations in target cells. The theme of the current study is to investigate the value of combining AIDS drugs and modifiers of cellular uptake into macromolecular conjugates having novel pharmacological properties.